Safety of anthelmintic medication during pregnancy: An evaluation of pregnancy outcomes based on the Embryotox cohort
- Conditions
- Q89.9O03P95Congenital malformation, unspecifiedSpontaneous abortionFetal death of unspecified cause
- Registration Number
- DRKS00032898
- Lead Sponsor
- Pharmakovigilanz- und Beratungszentrum für Embryonaltoxikologie Charité – Universitätsmedizin Berlin
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 323
Inclusion Criteria
Contact with Embryotox Center of Clinical Teratology and Drug Safety in Pregnancy, Berlin for consultation in pregnancy during the study period (01.01.2000 - 28.02.2023) and exposure to study medication during pregnancy.
At first contact with Embryotox Center of Clinical Teratology and Drug Safety in Pregnancy, the pregnancy outcome is unknown and there are no reported pathological findings. Information on pregnancy outcome is completed; quality of information/data must meet internal standards.
Exclusion Criteria
Non-plausible or missing relevant data.
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Congenital malformations, spontaneous abortions, stillbirths
- Secondary Outcome Measures
Name Time Method Birth weight, head circumference, gestational age at delivery, other pregnancy complications, e.g. intrauterine growth retardation (IUGR)